EzraEwCohenMD

Oncology • La Jolla, CA

Head & Neck Cancer, Hematologic Oncology

Professor of Medicine, UC San Diego // Associate Director, Translational Science at Moores Cancer Center

Join to view full profile

Dr. Cohen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cohen's full profile

Already have an account?

Office
3855 Health Sciences Dr
La Jolla, CA 92093
Phone+1 858-534-3804

Summary

I am a board-certified oncologist and cancer researcher. I care for patients with all types of head and neck cancers, including esophageal, thyroid and salivary gland cancers.

Much of my work has focused on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. As a physician-scientist, he is especially interested in developing novel therapies and understanding mechanisms of sensitivity or resistance; cancer screening; and using medication and other agents to delay or prevent cancer (chemoprevention). Additionally, I was recently appointed chair of the National Cancer Institute Head and Neck Cancer Steering Committee, which oversees NCI-funded clinical research in this disease.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1999 - 2002
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1996 - 1999
University of Toronto Faculty of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 2014 - 2026
IL State Medical License 1999 - 2026
MA State Medical License 2011 - 2017
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) Start of enrollment: 2004 Nov 01
Completed
Phase 3
Rapamycin With Grapefruit Juice for Advanced Malignancies Start of enrollment: 2006 Sep 01
Completed
Phase 1
Erlotinib Prevention of Oral Cancer (EPOC) Start of enrollment: 2006 Nov 03
Completed
Phase 3
Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2005 Mar 01
Completed
Phase 2
Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers Start of enrollment: 2007 Oct 01
Completed
Early Phase 1
The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer Start of enrollment: 2006 Jun 01
Terminated
Not Applicable
Rapamycin Plus Bevacizumab in Advanced Cancers Start of enrollment: 2008 Apr 01
Completed
Phase 1
Study of Rapamycin Plus Ketoconazole in Advanced Cancers Start of enrollment: 2004 Oct 01
Completed
Phase 1
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck Start of enrollment: 2010 May 04
Terminated
Phase 2
Evaluation of Food Effect on Pharmacokinetics of Vismodegib Start of enrollment: 2009 Oct 01
Completed
Phase 1, Phase 2
Feasibility of Imaging in the Treatment of Patients With Advanced Head and Neck Cancer Start of enrollment: 2011 Apr 19
Completed
Early Phase 1
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions Start of enrollment: 2012 Jan 01
Completed
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
Pembrolizumab in Treating Participants With Leukoplakia Start of enrollment: 2019 May 03
Recruiting
Phase 2
SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2020 Jul 02
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the P...
Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder
Journal for Immunotherapy of Cancer. 2024-11-03
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma.
Michael J Dennis, Dean C Pavlick, Alec Kacew, Michael Wotman, Laura E MacConaill
Journal of Translational Medicine. 2024-10-22
1 citations
An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
Karen M Yun, Ezra E W Cohen
JCO Oncology Practice. 2024-07-01

Lectures

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naÃ¯ve patients with recurrent or metastatic ...
2019 ASCO Annual Meeting - 6/1/2019
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) i...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/met...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Press Mentions

Tempus Scores a Win with Blue Cross PlansDecember 18th, 2024
Tempus Announces Four Abstracts Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumDecember 10th, 2024
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual MeetingNovember 8th, 2024
Join now to see all